Killer peptide: A novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs

Future Medicinal Chemistry

Volumn 3, Issue 9, 2011, Pages 1209-1231

  Magliani, Walter ^a   Conti, Stefania ^a   Ciociola, Tecla ^a   Giovati, Laura ^a   Zanello, Pier Paolo ^a   Pertinhez, Thelma ^a   Spisni, Alberto ^a   Polonelli, Luciano ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ANTIIDIOTYPIC ANTIBODY; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BETA DEFENSIN; BETA GLUCAN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HISTATIN; IMMUNOMODULATING AGENT; KILLER PEPTIDE; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; YEAST KILLER FACTOR;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; CANDIDIASIS; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DRUG BIOAVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; IMMUNOMODULATION; INNATE IMMUNITY; MEMBRANE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTI-INFECTIVE AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; BETA-GLUCANS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; KILLER FACTORS, YEAST; MOLECULAR TARGETED THERAPY; PEPTIDES;

EID: 79961099517     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.71     Document Type: Review

References (178)

1. Culotta E. Funding crunch hobbles antibiotic resistance research. Science 264, 362-363 (1994). (Pubitemid 24178892)
2. Bax RP. Antibiotic resistance: a view from the pharmaceutical industry. Clin. Infect. Dis. 24(Suppl. 1), S5151-S5153 (1997).
3. Cohen ML. Changing patterns of infectious disease. Nature 406, 762-767 (2000).
4. Zanetti AR, Zappa A. Emerging and re-emerging infections at the turn of the millennium. Haemophilia 16(Suppl. 1), 7-12 (2010).
5. Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature 447, 279-283 (2007). (Pubitemid 46788835)
6. Jones KE, Patel NG, Levy MA et al. Global trends in emerging infectious diseases. Nature 451, 990-993 (2008). (Pubitemid 351301726)
7. Pohanka M, Kuca K. Biological warfare agents. EXS 100, 559-578 (2010).
8. Woolhouse M, Gaunt E. Ecological origins of novel human pathogens. Crit. Rev. Microbiol. 33, 231-242 (2007). (Pubitemid 350146703)
9. Fauci AS. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32, 675-685 (2001). (Pubitemid 32221924)
10. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164, 2008. (Pubitemid 351269151)
11. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
12. Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol. 12, 476-481 (2009).
13. Kumar D. Emerging viruses in transplantation. Curr. Opin. Infect. Dis. 23, 374-378 (2010).
14. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36, 1-53 (2010).
15. Broder S. The development of antiretroviral therapy and its impact on the global HIV-1/ AIDS pandemic. Antiviral Res. 85, 1-18 (2010).
16. Nathan C. Antibiotics at the crossroads. Nature 431, 899-902 (2004). (Pubitemid 39434399)
17. Czerepak EA, Ryser S. Drug approvals and failures: implications for alliances. Nature Rev. Drug Discov. 7, 197-198 (2008). (Pubitemid 351321230)
18. Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003). (Pubitemid 37345405)
19. Service RF. Surviving the blockbuster sindrome. Science 303, 1796-1799 (2004).
20. Loferer H. Mining bacterial genomes for antimicrobial targets. Mol. Med. Today 12, 470-474 (2000).
21. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 325, 1089-1093 (2009).
22. Rahman H, Austin B, Mitchell WJ et al. Novel anti-infective compounds from marine bacteria. Mar. Drugs 8, 498-518 (2010).
23. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007). (Pubitemid 46020284)
24. Gross H. Genomic mining - a concept for the discovery of new bioactive natural products. Curr. Opin. Drug Discov. Devel. 12, 207-219 (2009).
25. Hammami R, Fliss I. Current trends in antimicrobial agent research: chemo- and bioinformatics approaches. Drug Discov. Today 15, 540-546 (2010).
26. Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc. R. Soc. Lond. (Biol.) 93, 306-317 (1922).
27. Skarks RC, Watson DW. Antimicrobial factors of normal tissues and fluids. Bacteriol. Rev. 21, 273-294 (1957).
28. Zeya HI, Spitznagel JK. Antibacterial and enzymic basic proteins from leukocyte lysosomes: separation and identification. Science 142, 1085-1087 (1963).
29. Hultmark D, Steiner H, Rasmuson T, Boman HG. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur. J. Biochem. 106, 7-16 (1980). (Pubitemid 10057882)
30. Selsted ME, Brown DM, DeLange RJ, Lehrer RI. Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. J. Biol. Chem. 258, 14485-14489 (1983). (Pubitemid 14220295)
31. Zasloff M. Antimicrobial peptides of multicellular organisms. ature 415, 389-395 (2002). (Pubitemid 34100944)
32. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18, 24-30 (2006). (Pubitemid 43049644)
33. Steistraesser L, Kraneburg UM, Hirsch T et al. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci. 10, 3951-3970 (2009).
34. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 1778, 357-375 (2008).
35. Bucki R, Levental I, Janmey PA. Antibacterial peptides - a bright future or a false hope. Anti-Infect. Agents Med. Chem. 6, 175-184 (2007). (Pubitemid 47099055)
36. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254, 197-215 (2003). (Pubitemid 37070221)
37. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3, 238-250 (2005). (Pubitemid 40298223)
38. Sahl HG, Pag U, Bonness S, Wagner S, Antcheva N, Tossi A. Mammalian defensins: structures and mechanism of antibiotic activity. J. Leukoc. Biol. 77, 466-475 (2005). (Pubitemid 40489522)
39. Hale JD, Hancock REW. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 5, 951-959 (2007). (Pubitemid 350303026)
40. Hilpert K, McLeod B, Yu J et al. Short cationic antimicrobial peptides interact with ATP. Antimicrob. Agents Chemother. 54, 4480-4483 (2010).
41. Dorschner RA, Lopez-Garcia B, Peschel A et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J. 20, 35-42 (2006). (Pubitemid 43100473)
42. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55 (2003). (Pubitemid 36268398)
43. Xu F, Meng K, Wang Y-R et al. Eukaryotic expression and antimicrobial spectrum determination of the peptide tachyplesin II. Prot. Express. Purific. 58, 175-183 (2008).
44. Aerts AM, Francois IE, Cammue BP, Thevissen K. The mode of antifungal action of plant, insect and human defensins. Cell. Mol. Life Sci. 65, 2069-2079 (2008).
45. Thevissen K, Warnecke DC, Francois IE et al. Defensins from insects and plants interact with fungal glucosylceramides. J. Biol. Chem. 279, 3900-3905 (2004). (Pubitemid 38198972)
46. Lobo DS, Pereira IB, Fragel-Madeira L et al. Antifungal Pisum sativum defensin 1 interacts with Neurospora crassa cyclin F related to the cell cycle. Biochemistry 46, 987-996 (2007). (Pubitemid 46184986)
47. Tavares PM, Thevissen K, Cammue BP et al. In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis. Antimicrob. Agents Chemother. 52, 4522-4525 (2008).
48. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6, 447-456 (2006).
49. Wang W, Owen SM, Rudolph DL et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J. Immunol. 173, 515-520 (2004). (Pubitemid 38797379)
50. Yasin B, Wang W, Pang M et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78, 5147-5156 (2004). (Pubitemid 38581467)
51. Hazrati E, Galen B, Lu W et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177, 8658-8666 (2006). (Pubitemid 44893830)
52. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul. Pept. 101, 157-161 (2001). (Pubitemid 32728382)
53. Buck CB, Day PM, Thompson CD et al. Human alpha-defensins block papillomavirus infection. Proc. Natl Acad. Sci. USA 103, 1516-1521 (2006). (Pubitemid 43191197)
54. Dugan AS, Maginnis MS, Jordan JA et al. Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. J. Biol. Chem. 283, 31125-31132 (2008).
55. Smith JG, Silvestry M, Lindert S, Lu W, Nemerow GR, Stewart PL. Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog. 6(6), e1000959 (2010).
56. Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob. Agents Chemother. 54, 1343-1346 (2010).
57. Hirsch JG. Bactericidal action of histone. J. Exp. Med. 108, 925-944 (1958).
58. Frohm M, Gunne H, Bergman A-C et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur. J. Biochem. 237, 86-92 (1996). (Pubitemid 26110276)
59. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL. Human high-density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J. Biol. Chem. 280, 32578-32585 (2005). (Pubitemid 41368299)
60. Kelly BA, Harrison I, McKnight A, Dobson CB. Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity. BMC Immunol. 11: 13 (2010).
61. Yang D, Chen Q, Hoover DM et al. Many chemokines including CCL20/MIP-3a display antimicrobial activity. J. Leukoc. Biol. 74, 448-455 (2003). (Pubitemid 38040406)
62. Flad HD, Brandt E. Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell. Mol. Life Sci. 67, 2363-2386 (2010).
63. Gonzalez-Rey E, Ganea D, Delgado M. Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. Curr. Opin. Pharmacol. 10, 473-481 (2010).
64. Nordahl EA, Rydengård V, Nyberg P et al. Activation of the complement system generates antibacterial peptides. Proc. Natl Acad. Sci. USA 101, 16879-16884 (2004). (Pubitemid 39601332)
65. Malmsten M, Davoudi M, Walse B et al. Antimicrobial peptides derived from growth factors. Growth Factors 25, 60-70 (2007). (Pubitemid 46672287)
66. Nordahl EA, Rydengård V, Mörgelin M, Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial. J. Biol. Chem. 280, 34832-34839 (2005). (Pubitemid 41504617)
67. Liepke C, Baxmann S, Heine C, Breithaupt N, Ständker L, Forssmann WG. Human hemoglobin-derived peptides exhibit antimicrobial activity: a class of host defense peptides. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 791, 345-356 (2003). (Pubitemid 36638767)
68. Ständker L, Zachgo V, Hillemanns P, Rösinger M, Forssmann WG, Hass R. Quantitative enzyme-linked immunosorbent assay determination of an abundant hemoglobin-derived anti-infective peptide in human placenta. Anal. Biochem. 401, 53-60 (2010).
69. Papareddy P, Rydengård V, Pasupuleti M et al. Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog. 6, e1000857 (2010).
70. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3, 215-225 (2004). (Pubitemid 38379988)
71. Lu J, Deeks SG, Hoh R et al. Rapid emergence of enfuvirtide resistance in HIV- 1-infected patients: results of a clonal analysis. J. Acquir. Immune Defic. Syndr. 43, 60-64 (2006). (Pubitemid 44306489)
72. Lambert DM, Barney S, Lambert AL et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl Acad. Sci. USA 93, 2186-2191 (1996). (Pubitemid 26079903)
73. Weissenhorn W, Carfí A, Lee KH, Skehel JJ, Wiley DC. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell. 2, 605-616 (1998). (Pubitemid 128379086)
74. Xu Y, Gao S, Cole DK et al. Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem. Biophys. Res. Commun. 315, 664-670 (2004). (Pubitemid 38229395)
75. Liu S, Xiao G, Chen Y et al. Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implication for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938-947 (2004). (Pubitemid 38388327)
76. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 84, 2017-2020 (1989). (Pubitemid 20016213)
77. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005). (Pubitemid 40848537)
78. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451-459 (2005). (Pubitemid 40489520)
79. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216, 322-333 (2011).
80. Rehaume LM, Hancock REW. Neutrophil-derived defensins as modulators of innate immune function. Crit. Rev. Immunol. 28, 185-200 (2008).
81. Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr. Pharm. Des. 15, 2377-2392 (2009).
82. Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with non immunogenic tumor antigens. J. Immunol. 167, 6644-6653 (2001). (Pubitemid 33081603)
83. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell. Mol. Life Sci. 58, 978-989 (2001). (Pubitemid 32652821)
84. Davidson DJ, Currie AJ, Reid GS et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146-1156 (2004). (Pubitemid 38113775)
85. Tani K, Murphy WJ, Chertov O et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. 12, 691-700 (2000). (Pubitemid 30248902)
86. Scott MG, Dullaghan E, Mookherjee N et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25, 465-472 (2007). (Pubitemid 46572850)
87. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 64, 922-933 (2007). (Pubitemid 46597762)
88. Magliani W, Conti S, Cunha RL, Travassos LR, Polonelli L. Antibodies as crypts of antiinfective and antitumor peptides. Curr. Med. Chem. 16, 2305-2323 (2009).
89. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon? Methods Mol. Biol. 525, 1-27 (2009).
90. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767-774 (2010).
91. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10, 345-352 (2010).
92. Nevinsky GA, Buneva VN. Natural catalytic antibodies in norm, autoimmune, viral, and bacterial diseases. ScientificWorldJournal 10, 1203-1233 (2010).
93. Magliani W, Conti S, Frazzi R, Ravanetti L, Maffei DL, Polonelli L. Protective antifungal yeast killer toxin-like antibodies. Curr. Mol. Med. 5, 443-452 (2005). (Pubitemid 40846925)
94. Brena S, Omaetxebarría MJ, Elguezabal N, Cabezas J, Moragues MD, Pontön J. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect. Immun. 75, 3680-3682 (2007). (Pubitemid 47040972)
95. Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J. Mol. Biol. 377, 1518-1528 (2008).
96. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136 (2005). (Pubitemid 41486394)
97. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 8, 600-608 (2008).
98. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl Acad. Sci. USA 105, 17121-17126 (2008).
99. Wesolowski J, Alzogaray V, Reyelt J et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198, 157-174 (2009).
100. Chen W, Zhu Z, Feng Y, Dimitrov DS. A large human domain antibody library combining heavy and light chain CDR3 diversity. Mol. Immunol. 47, 912-921 (2010).
101. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol. 25, 921-929 (2007). (Pubitemid 47236913)
102. Ladner RC. Antibodies cut down to size. Nat. Biotechnol. 25, 875-877 (2007). (Pubitemid 47236907)
103. Kang CY, Brunck TK, Kieber-Emmons T, Blalock JE, Kohler H. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 240, 1034-1036 (1988).
104. Bourgeois C, Bour JB, Aho LS, Pothier P. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J. Virol. 72, 807-810 (1998). (Pubitemid 28048904)
105. Dorfman T, Moore MJ, Guth AC, Choe H, Farzan M. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J. Biol. Chem. 281, 28529-28535 (2006). (Pubitemid 44506995)
106. Heap CJ, Wang Y, Pinheiro TJ, Reading SA, Jennings KR, Dimmock NJ. Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J. Gen. Virol. 86, 1791-1800 (2005). (Pubitemid 40766892)
107. Deroo S, Fischer A, Beaupain N et al. Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope. Mol. Immunol. 45, 1366-1373 (2008).
108. Polonelli L, Magliani W, Conti S et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71, 6205-6212 (2003). (Pubitemid 37337676)
109. Polonelli L, Pontön J, Elguezbal N et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One 3, e2371 (2008).
110. Gabrielli E, Pericolini E, Cenci E et al. Antibody complementarity- determining regions (CDRs): a bridge between adaptive and innate immunity. PLoS One 4, e8187 (2009).
111. Dobroff AS, Rodrigues EG, Juliano MA et al. Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells. Transl. Oncol. 3, 204-217 (2010).
112. Schmidtchen A, Pasupuleti M, Mörgelin M et al. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. Biol. Chem. 284, 17584-17594 (2009).
113. Zhang L, Falla TJ. Host defense peptides for use as potential therapeutics. Curr. Opin. Investig. Drugs 10, 164-171 (2009).
114. Jenssen H, Hancock RE. Therapeutic potential of HDPs as immunomodulatory agents. Methods Mol. Biol. 618, 329-347 (2010).
115. Matejuk A, Leng Q, Begum MD et al. Peptide-based antifungal therapies against emerging infections. Drugs Future 35, 197 (2010).
116. Yount NY, Bayer AS, Xiong YQ, Yeaman MR. Advances in antimicrobial peptide immunobiology. Biopolymers 84, 435-458, (2006). (Pubitemid 44519206)
117. Peschel A. How do bacteria resist human antimicrobial peptides? Trends Microbiol. 10, 179-186 (2002). (Pubitemid 34242955)
118. Steinstraesser L, Kraneburg UM, Hirsch T et al. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci. 10, 3951-3970 (2009).
119. Bommarius B, Jenssen H, Elliott M et al. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 31, 1957-1965 (2010).
120. Giuliani A, Pirri G, Bozzi A, Di Giulio A, Aschi M, Rinaldi AC. Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell. Mol. Life Sci. 65, 2450-2460 (2008).
121. Scott RW, DeGrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19, 620-627 (2008).
122. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788, 1582-1592 (2009).
123. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 37, D933-937 (2009).
124. Duclohier H. Antimicrobial peptides and peptaibols, substitutes for conventional antibiotics. Curr. Pharm. Des. 16, 3212-3223 (2010).
125. Tew GN, Scott RW, Klein ML, Degrado WF. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc. Chem. Res. 43, 30-39 (2010).
126. Langham A, Kaznessis YN. Molecular simulations of antimicrobial peptides. Methods Mol. Biol. 618, 267-285 (2010).
127. Brouwer CP, Sarda-Mantel L, Meulemans A, Le Guludec D, Welling MM. The use of technetium-99m radiolabeled human antimicrobial peptides for infection specific imaging. Mini Rev. Med. Chem. 8, 1039-1052 (2008).
128. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511 (2006). (Pubitemid 44137212)
129. Marcos JF, Munoz A, Pérez-Payá E, Misra S, Löpez-García B. Identification and rational design of novel antimicrobial peptides for plant protection. Annu. Rev. Phytopathol. 46, 273-301 (2008).
130. Zendo T, Yoneyama F, Sonomoto K. Lactococcal membrane-permeabilizing antimicrobial peptides. Appl. Microbiol. Biotechnol. 88, 1-9 (2010).
131. Kindrachuk J, Napper S. Structure-activity relationships of multifunctional host defence peptides. Mini Rev. Med. Chem. 10, 596-614 (2010).
132. Meng S, Xu H, Wang F. Research advances of antimicrobial peptides and applications in food industry and agriculture. Curr. Protein Pept. Sci. 11, 264-273 (2010).
133. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27-46 (2000). (Pubitemid 30326687)
134. Kashyap N, Kumar N, Kumar MN. Hydrogels for pharmaceutical and biomedical applications. Crit. Rev. Ther. Drug Carrier Syst. 22, 107-149 (2005). (Pubitemid 41568172)
135. Lin CC, Metters AT. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Deliv. Rev. 58, 1379-1408 (2006).
136. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 58, 1655-1670 (2006). (Pubitemid 44830149)
137. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels - review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 58, 409-426 (2004). (Pubitemid 39037244)
138. Zhang S, Holmes T, Lockshin C, Rich A. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl Acad. Sci. USA 90, 3334-3338 (1993). (Pubitemid 23111360)
139. Hauser CA, Zhang S. Designer self-assembling peptide nanofiber biological materials. Chem. Soc. Rev. 39, 2780-2790 (2010).
140. Zhao X, Pan F, Xu H et al. Molecular self-assembly and applications of designer peptide amphiphiles. Chem. Soc. Rev. 39, 3480-3498 (2010).
141. Maji SK, Schubert D, Rivier C, Lee S, Rivier JE, Riek R. Amyloid as a depot for the formulation of long-lasting drugs. PLoS Biol. 6(2), e17 (2008).
142. Salick DA, Kretsinger JK, Pochan DJ, Schneider JP. Inherent antibacterial activity of a peptide-based beta-hairpin hydrogel. J. Am. Chem. Soc. 129, 14793-14799 (2007). (Pubitemid 350207895)
143. Salick DA, Pochan DJ, Schneider JP. Design of an injectable b-hairpin peptide hydrogel that kills methicillin-resistant Staphylococcus aureus. Adv. Mater. 21, 4120-4123 (2009).
144. Bevan EA, Makower M. The physiological basis of the killer character in yeast. In: Proceedings of the 11th International Congress on Genetics 1, 202-203 (1963).
145. Magliani W, Conti S, Gerloni M, Bertolotti D, Polonelli L. Yeast killer systems. Clin. Microbiol. Rev. 10, 369-400 (1997). (Pubitemid 27359257)
146. Schmitt MJ, Breinig F. Yeast viral killer toxins: lethality and self-protection. Nat. Rev. Microbiol. 4, 212-221 (2006).
147. Lowes KF, Shearman CA, Payne J et al. Prevention of yeast spoilage in feed and food by the yeast mycocin HMK. Appl. Environ. Microbiol. 66, 1066-1076 (2000). (Pubitemid 30130028)
148. Buzzini P, Turchetti B, Vaughan-Martini AE. The use of killer sensitivity patterns for biotyping yeast strains: the state of the art, potentialities and limitations. FEMS Yeast Res. 7, 749-760 (2007). (Pubitemid 47256353)
149. Pettoello-Mantovani M, Nocerino A, Polonelli L et al. Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine. Gastroenterology 109, 1900-1906 (1995).
150. Polonelli L, Lorenzini R, De Bernardis F, Morace G. Potential therapeutic effect of yeast killer toxin. Mycopathologia 96, 103-107 (1986). (Pubitemid 17197247)
151. Selvakumar D, Miyamoto M, Furuichi Y, Komiyama T. Inhibition of fungal beta-1,3- glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob. Agents Chemother. 50, 3090-3097 (2006). (Pubitemid 44396416)
152. Magliani W, Conti S, Travassos LR, Polonelli L. From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol. Lett. 288, 1-8 (2008).
153. Krishnaswamy S, Kabir ME, Miyamoto M, Furuichi Y, Komiyama T. Different buffer effects in selecting HM-1 killer toxin single-chain fragment variable anti-idiotypic antibodies. J. Biochem. 147, 723-733 (2010).
154. Magliani W, Conti S, Giovati L, Maffei DL, Polonelli L. Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci. 13, 6920-6937 (2008).
155. Polonelli L, De Bernardis F, Conti S et al. Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol. 156, 1880-1885 (1996). (Pubitemid 26072556)
156. Torosantucci A, Bromuro C, Chiani P et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606 (2005). (Pubitemid 41258184)
157. Magliani W, Conti S, Salati A et al. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res. 5, 11-18 (2004). (Pubitemid 39285981)
158. Conti S, Magliani W, Giovati L et al. Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiol. 31, 143-145 (2008). (Pubitemid 351422084)
159. Manfredi M, McCullough MJ, Conti S et al. In vitro activity of a monoclonal killer antiidiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol. Immunol. 20, 226-232 (2005). (Pubitemid 40868396)
160. Cenci E, Bistoni F, Mencacci A et al. A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol. 6, 953-961 (2004). (Pubitemid 39255608)
161. Travassos LR, Silva LS, Rodrigues EG et al. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother. 54, 956-958 (2004). (Pubitemid 39529994)
162. Donini M, Lico C, Baschieri S et al. Production of an engineered killer peptide in Nicotiana benthamiana by using a Potato virus X expression system. Appl. Environ. Microbiol. 71, 6360-6367 (2005). (Pubitemid 41456937)
163. Magliani W, Conti S, Maffei DL et al. Antiidiotype-derived killer peptides as new potential tools to combat HIV-1 and AIDS-related opportunistic pathogens. Antiinf. Agents Med. Chem. 6, 263-272 (2007). (Pubitemid 47629309)
164. Savoia D, Scutera S, Raimondo S, Conti S, Magliani W, Polonelli L. Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Exp. Parasitol. 113, 186-192 (2006). (Pubitemid 43817976)
165. Fiori PL, Mattana A, Dessi D, Conti S, Magliani W, Polonelli L. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J. Antimicrob. Chemother. 57, 891-898 (2006).
166. Casoli C, Pilotti E, Perno CF et al. A killer mimotope with therapeutic activity against AIDS-related opportunistic microorganisms inhibits ex vivo HIV-1 replication. AIDS 20, 975-980 (2006).
167. Conti G, Magliani W, Conti S et al. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection. Antimicrob. Agents Chemother. 52, 4331-4337 (2008).
168. Cenci E, Pericolini E, Mencacci A et al. Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol. 79, 40-45 (2006). (Pubitemid 43054248)
169. Pertinhez TA, Conti S, Ferrari E, Magliani W, Spisni A, Polonelli L. Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol. Pharm. 6, 1036-1039 (2009).
170. Molina J, Cordero E, Pachön J. New information about the polymyxin/colistin class of antibiotics. Expert Opin. Pharmacother. 10, 2811-2828 (2009).
171. Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell. Mol. Life Sci. 66, 3821-3826 (2009).
172. Magliani W, Conti S, Salati A et al. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem. 11, 1793-1800 (2004). (Pubitemid 38821344)
173. Brötz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol. 5, 1553-1579 (2010).
174. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 324,1394-1395 (2009).
175. Vooturi SK, Firestine SM. Synthetic membrane-targeted antibiotics. Curr. Med. Chem. 17, 2292-2300 (2010).
176. Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr. Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob. Agents Chemother. 54, 1343-1346 (2010).
177. Timmerman P, Barderas R, Desmet J et al. A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity. J. Biol. Chem. 284, 34126-34134 (2009).
178. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. Recent advances in novel drug delivery systems. J. Nanotechnol. Online 2, 1-11 (2006).